Literature DB >> 3887593

Clonidine and guanfacine--comparison of their effects on haemodynamics in hypertension.

Y K Seedat.   

Abstract

The pharmacology of central alpha-adrenoceptor-stimulating agents is discussed, with particular reference to clonidine (Catapres; Boehringer Ingelheim) and guanfacine (Estulic; Sandoz), and their haemodynamic effects are compared and contrasted. The main differences between the effects of clonidine and guanfacine on hypertension are: guanfacine activates presynaptic alpha-adrenoceptors 10 times more selectively than clonidine; guanfacine has an alpha 2/alpha 1-selectivity ration 25 times higher than clonidine; clonidine decreases cardiac output and guanfacine decreases peripheral resistance, clonidine has no effect on stroke volume but guanfacine increases it; and when the clonidine withdrawal syndrome in the spontaneously hypertensive rat is compared with cessation of guanfacine treatment at an equipotent antihypertensive dose, the withdrawal syndrome after guanfacine appears later and is much less severe. Guanfacine may be preferable to clonidine as a central alpha-adrenoceptor stimulant in the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3887593

Source DB:  PubMed          Journal:  S Afr Med J


  4 in total

1.  Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals.

Authors:  Helen Fox; Mehmet Sofuoglu; Rajita Sinha
Journal:  J Psychopharmacol       Date:  2015-01-07       Impact factor: 4.153

Review 2.  The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.

Authors:  Helen Fox; Rajita Sinha
Journal:  Adv Pharmacol       Date:  2014

Review 3.  Central sympatholytic drugs.

Authors:  Wanpen Vongpatanasin; Kazuomi Kario; Steven A Atlas; Ronald G Victor
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-18       Impact factor: 3.738

Review 4.  Perspectives on research in hypertension.

Authors:  Y K Seedat
Journal:  Cardiovasc J Afr       Date:  2009 Jan-Feb       Impact factor: 1.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.